Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status
| Autor: | Shen, Xue Ning, Huang, Yu Yuan, Chen, Shi Dong, Guo, Yu, Tan, Lan, Dong, Qiang, Yu, Jin Tai, Weiner, Michael W., Aisen, Paul, Petersen, Ronald, Jack, Clifford R., Jagust, William, Trojanowki, John Q., Toga, Arthur W., Beckett, Laurel, Green, Robert C., Saykin, Andrew J., Morris, John C., Perrin, Richard J., Shaw, Leslie M., Carrillo, Maria, Potter, William, Barnes, Lisa, Bernard, Marie, González, Hector, Ho, Carole, Hsiao, John K., Jackson, Jonathan, Masliah, Eliezer, Masterman, Donna, Okonkwo, Ozioma |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pathology
medicine.medical_specialty Aging Screening test Amyloid Clinical Sciences S amyloid Neurosciences. Biological psychiatry. Neuropsychiatry tau Proteins Neurodegenerative Predictive markers Alzheimer's Disease Article Cellular and Molecular Neuroscience Alzheimer Disease Fluorodeoxyglucose F18 Clinical Research Acquired Cognitive Impairment Medicine Humans Psychology Pathological Biological Psychiatry Predictive biomarker screening and diagnosis Amyloid beta-Peptides business.industry Neurosciences Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Diagnostic markers Alzheimer’s Disease Neuroimaging Initiative Brain pathologies Pathophysiology Brain Disorders 4.1 Discovery and preclinical testing of markers and technologies Psychiatry and Mental health Detection Neurological Public Health and Health Services Phosphorylation Biomedical Imaging Dementia business Biomarkers RC321-571 4.2 Evaluation of markers and technologies |
| Zdroj: | Translational psychiatry, vol 11, iss 1 Translational Psychiatry, Vol 11, Iss 1, Pp 1-10 (2021) Medical Biophysics Publications Translational Psychiatry |
| Popis: | Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer’s diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed to evaluate whether it could serve as a marker for Alzheimer’s pathology in the brain. A total of 1189 participants with plasma p-tau181 and PET data of amyloid, tau or FDG PET were included from ADNI. Cross-sectional relationships of plasma p-tau181 with PET biomarkers were tested. Longitudinally, we further investigated whether different p-tau181 levels at baseline predicted different progression of Alzheimer’s pathological changes in the brain. We found plasma p-tau181 significantly correlated with brain amyloid (Spearman ρ = 0.45, P P = 0.0003), and FDG PET uptakes (−0.37, P 18.85 pg/ml) at baseline had a higher risk of pathological progression in brain amyloid (HR: 2.32, 95%CI 1.32–4.08) and FDG PET (3.21, 95%CI 2.06–5.01) status. Plasma p-tau181 may be a sensitive screening test for detecting brain pathologies, and serve as a predictive biomarker for Alzheimer’s pathophysiology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|